ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2016
Efficacy of Intravenous Immunoglobulin in Neurological Diseases.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of blood derivatives therapy in Alzheimer's disease: a systematic review and meta-analysis.Systematic reviews · 2022Pooled it
- Hereditary transthyretin amyloidosis mimicking ALS: First genetically proven case report from Saudi Arabia.eNeurologicalSci · 2026Article
- Drug repurposing for disease-modifying effects in multiple system atrophy.Translational neurodegeneration · 2026Review
- A Clinician Perspective for a Personalized Approach to Management of Chronic Immune Thrombocytopenia with Targeted Therapies Alone or in Combination.Journal of clinical medicine · 2026Review
- The effect of high-dose long-term therapy of intravenous immunoglobulins in autoimmune autonomic and sensory small fiber neuropathy: a retrospective open-label controlled study.Scientific reports · 2025Article
- COVID-19-associated Autoimmune and Inflammatory Diseases: Molecular Mechanisms and the Role of IVIG Therapy.Clinical reviews in allergy & immunology · 2025Review
- The anti-inflammatory activity of IgG is enhanced by co-engagement of type I and II Fc receptors.Science (New York, N.Y.) · 2025Article
- Intravenous immunoglobulin for the acute treatment of refractory optic neuritis in Japan.Japanese journal of ophthalmology · 2025Article
- Genetic variation of low-to-medium-affinity Fc-gamma receptors in Guillain-Barré syndrome.Journal of neurology · 2025Article
- Intravenous immunoglobulin as first-line acute treatment in adults with autoimmune encephalitis caused by antibodies to NMDAR, LGI1 and CASPR2.Journal of neurology · 2025Article
- Role of intravenous immunoglobulins in the management of systemic lupus erythematosus: a single-centre experience.Lupus science & medicine · 2024Article
- Short delay to initiate plasma exchange or immunoadsorption as synergistic therapies for patients in the acute phase of anti-NMDAR encephalitis.Therapeutic advances in neurological disorders · 2024Article
- Review
- IVIg-induced headache: prospective study of a large cohort with neurological disorders.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- Long-Term Outcome of Pediatric Patients with Anti-NMDA Receptor Encephalitis in a Single Center.Children (Basel, Switzerland) · 2023Article
- The use of intravenous immunoglobulin in the treatment of Hashimoto's encephalopathy: case based review.Frontiers in neurology · 2023Review
- Efficacy of intravenous immunoglobulin (IVIg) on COVID-19-related neurological disorders over the last 2 years: an up-to-date narrative review.Frontiers in neuroscience · 2023Review
- Using a scenario approach to assess for the current and future demand of immunoglobulins: An interview and literature study from The Netherlands.Transfusion medicine (Oxford, England) · 2022Review
- Autoimmune Neurogenic Dysphagia.Dysphagia · 2022Review
- Next-generation antibody-based therapies in neurology.Brain : a journal of neurology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Owing to its anti-inflammatory efficacy in various autoimmune disease conditions, intravenous immunoglobulin (IVIG)-pooled IgG obtained from the plasma of several thousands individuals-has been used for nearly three decades and is proving to be efficient in a growing number of neurological diseases. IVIG therapy has been firmly established for the treatment of Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy, either as first-line therapy or adjunctive treatment. IVIG is also recommended as rescue therapy in patients with worsening myasthenia gravis and is beneficial as a second-line therapy for dermatomyositis and stiff-person syndrome. Subcutaneous rather than intravenous administration of IgG is gaining momentum because of its effectiveness in patients with primary immunodeficiency and the ease with which it can be administered independently from hospital-based infusions. The demand for IVIG therapy is growing, resulting in rising costs and supply shortages. Strategies to replace IVIG with recombinant products have been developed based on proposed mechanisms that confer the anti-inflammatory activity of IVIG, but their efficacy has not been tested in clinical trials. This review covers new developments in the immunobiology and clinical applications of IVIG in neurological diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.